Menu
Search
|

Menu

Close
X

Retrophin Inc RTRX.OQ (NASDAQ Stock Exchange Global Market)

22.34 USD
-0.63 (-2.74%)
As of 3:59 PM EST
chart
Previous Close 22.97
Open 23.14
Volume 90,480
3m Avg Volume 99,100
Today’s High 23.25
Today’s Low 22.32
52 Week High 26.43
52 Week Low 15.57
Shares Outstanding (mil) 39.31
Market Capitalization (mil) 902.87
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.50 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
113
FY16
134
FY15
100
EPS (USD)
FY17
-1.091
FY16
-1.287
FY15
2.976
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
34.75
Price to Sales (TTM)
vs sector
6.02
8.23
Price to Book (MRQ)
vs sector
2.96
5.26
Price to Cash Flow (TTM)
vs sector
--
26.16
Total Debt to Equity (MRQ)
vs sector
14.75
15.44
LT Debt to Equity (MRQ)
vs sector
14.75
12.05
Return on Investment (TTM)
vs sector
-11.49
13.63
Return on Equity (TTM)
vs sector
-16.57
15.25

EXECUTIVE LEADERSHIP

Gary Lyons
Independent Chairman of the Board, Since 2016
Salary: --
Bonus: --
Stephen Aselage
President, Chief Executive Officer, Director, Since 2014
Salary: $510,417.00
Bonus: --
Laura Clague
Chief Financial Officer, Senior Vice President, Since 2014
Salary: $368,000.00
Bonus: --
Neil McFarlane
Chief Operating Officer, Since 2016
Salary: $179,952.00
Bonus: $100,000.00
Elizabeth Reed
Senior Vice President, General Counsel and Corporate Secretary, Since 2017
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

3721 Valley Centre Dr Ste 200
SAN DIEGO   CA   92130-3330

Phone: +1760.2608600

Retrophin, Inc. is a biopharmaceutical company. The Company is focused on the development, acquisition and commercialization of therapies for the treatment of serious, catastrophic or rare diseases. The Company sells three products, including Chenodal (chenodeoxycholic acid), Cholbam (cholic acid) and Thiola (tiopronin). Its Chenodal is approved in the United States for the treatment of patients suffering from gallstones in whom surgery poses an unacceptable health risk due to disease or advanced age. Chenodal has also been care for cerebrotendinous xanthomatosis (CTX) patients. Its Cholbam is approved in the United States for the treatment of bile acid synthesis disorders due to single enzyme defects and is further indicated for adjunctive treatment of patients with peroxisomal disorders. Its Thiola is approved in the United States for the prevention of cystine (kidney) stone formation in patients with severe homozygous cystinuria.

SPONSORED STORIES